Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00243555|
Recruitment Status : Unknown
Verified September 2006 by McMaster University.
Recruitment status was: Recruiting
First Posted : October 24, 2005
Last Update Posted : February 1, 2007
|Condition or disease||Intervention/treatment|
|Peanut Hypersensitivity||Procedure: allergy skin testing Procedure: venepuncture|
Peanut allergy occurs in about 1% of the population. Allergic reactions to peanuts and tree nuts account for the majority of fatal and near fatal food allergic reactions. Currently the only available treatment is complete avoidance of peanut. Despite avoidance, the majority of peanut allergic people will accidentally ingest peanut. Accurate diagnosis is critical, yet often problematic. Current diagnostic methods such as skin and blood tests cannot predict definitively who is allergic and can result in patients being falsely labeled. One such group is children who have never been exposed to peanut as a means of preventing allergy, yet have positive skin tests. The only means of definitively diagnosing this group is with an oral peanut challenge, a potentially risky procedure. Previous studies have demonstrated differences in certain genes and growth factors between peanut allergic and non-allergic individuals. The proposed study has 2 phases. The first phase, almost completed, examines expression of genes and growth factors in defined groups of peanut allergic and non-allergic individuals which should help distinguish between these groups. Peripheral blood mononuclear cells from each patient will be cultured and analyzed for a variety of growth factors and other immune molecules, including mRNA, thought to be important in allergy.
The second phase of this study will involve feeding peanut to individuals with positive skin tests, who have never been peanut exposed. Their blood will be examined before and after the challenge using information from Part 1, and results will be correlated with their ability to tolerate peanut on feeding. This study should enable us to better predict who is truly peanut allergic.
There are four groups of patients in this study. Group 1 consists of individuals who are allergic to peanut. This group of individuals will have a positive skin test to peanut and a previous allergi reaction to peanut. Group 2 consists of indivduals who have a positive skin test to peanut but who are able to ingest peanuts without problems. Group 3 consists of individuals who have a positive skin test to peanut but who have no known ingestion of peanut and who have avoided peanut lifelong for whatever reason (e.g. a strong family history of peanut allergy). Lastly, group 4 consists of control subjects who are negative to the peanut skin test and are able to tolerate peanut without problems.
|Study Type :||Observational|
|Enrollment :||60 participants|
|Observational Model:||Defined Population|
|Official Title:||Molecular Analysis of Immuno-Regulatory Genes Expressed by Mononuclear Cells From Peanut Skin Test Positive Individuals With and Without a History of Peanut Ingestion|
|Study Start Date :||September 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00243555
|Contact: Andrea Marin, MD||905-521-2100 ext 75642|
|Hamilton Health Sciences Corporation, McMaster Site||Recruiting|
|Hamilton, Ontario, Canada, L8N 3Z5|
|Contact: Marie Townsend 905-525-9140 ext 22465 email@example.com|
|Contact: Deidre L. Henne 905-521-2100 ext 74595 firstname.lastname@example.org|
|Principal Investigator:||Susan Waserman, MSc, MD, FRCPC||Hamilton Health Sciences Corporation, McMaster Site|